18 results about "Macrophage colony-stimulating factor" patented technology

Embodiments of the instant disclosure relate to intervention and / or treatment of autism spectrum disorder (ASD). Certain embodiments relate to treating a subject having ASD with one or more proinflammatory cytokines. In some embodiments, the one or more proinflammatory cytokines include, but are not limited to, granulocyte-macrophage colony-stimulating factor (GM-CSF) or derivative thereof, or fusion polypeptide thereof, or recombinant thereof. Other embodiments include a mouse model for assessing efficacy of treatment of ASD in humans and other mammals.

The present invention relates to gene therapy agents for the treatment of pulmonary alveolar proteinosis (PAP), particularly autoimmune PAP (aPAP). In particular, the present invention relates to gene therapy vectors which drive transient and / or low-level expression of granulocyte-macrophage colony-stimulating factor (GM-CSF), which provide a therapeutic effect without therapy-associated toxicity. The invention further relates to related products and an animal model of aPAP.

The invention provides a granulocyte-macrophage colony stimulating factor antibody and application thereof, and belongs to the technical field of biological medicine. A granulocyte-macrophage colony stimulating factor (GM-CSF) antibody or fragment has high affinity, can effectively block GM-CSF / GM-CSF receptor interaction, and has low immunogenicity. The GM-CSF antibody or fragment can be used for preventing and / or treating diseases caused by human GM-CSF or detecting human GM-CSF protein or diagnosing related diseases caused by the human GM-CSF protein.

This invention relates to the field of cell biology, specifically to a co-culture cell model and method for primary glial cells and neurons. The method for co-culturing primary glial cells and neurons provided by this invention includes the following steps: a mixture of primary glial cells and neurons is seeded into a first co-culture medium for pre-culture; the medium is discarded and the cells are washed; a second co-culture medium is added for a first-stage culture; after the first-stage culture, a second-stage culture is performed; the medium used in the second-stage culture is a third co-culture medium supplemented with macrophage colony-stimulating factor; after the second-stage culture, a third-stage culture is performed; the medium used in the third-stage culture is the second co-culture medium; in the obtained co-culture cell model, microglia are differentiated and mature, and are in a quiescent state, thus obtaining a primary glial cell and neuron co-culture model.

The invention relates to a construction method of a peripheral red blood cell humanized mouse, which comprises the following steps: transplanting human hematopoietic stem cells into the mouse and then applying a red blood cell inducer to the mouse, or applying a red blood cell inducer to the mouse and then infusing human red blood cells into the mouse. The red blood cell inducer comprises an antibody targeting mouse macrophage, dexamethasone or a derivative thereof, and a human macrophage colony stimulating factor. In a mouse transplanted with human hematopoietic stem cells, one or more of an antibody targeting mouse macrophages, dexamethasone and a human macrophage colony stimulating factor can be used in the red blood cell induced maturation process, and high-level human red blood cell reconstruction can be quickly realized within three weeks; the maturity and the denucleation ratio of peripheral human erythrocytes reconstructed in the mouse are completely consistent with those of normal human blood; in a mouse transplanted with human erythrocytes, the erythrocyte induction process can be single treatment of an antibody or dexamethasone, or combined use of the antibody and dexamethasone. The invention also provides application of the peripheral erythrocyte humanized mouse.

The present application relates to the technical field of immune detection, and particularly relates to a granulocyte-macrophage colony stimulating factor determination kit and a detection method thereof. The granulocyte-macrophage colony stimulating factor determination kit comprises GM-CSF magnetic microparticles, GM-CSF luminescent markers, an analysis buffer, a calibrant 1, a calibrant 2, a quality control 1 and a quality control 2. The GM-CSF magnetic microparticles, a sample or the calibrant or the quality control and the analysis buffer are sequentially added, and after incubation and cleaning, the GM-CSF luminescent markers are added for incubation and cleaning, and then the substrate A liquid and the substrate B liquid are sequentially added, and the luminescence intensity is immediately measured, the GM-CSF concentration is calculated according to a calibration curve, the total detection time can be controlled to be about 1 hour, the detection efficiency is greatly improved, and the method can better meet the needs of clinical emergency and high-speed screening. The detection method is simple in operation, fast and accurate in result, and easy to realize automatic high-throughput detection.

Provided are an oncolytic virus preparation capable of crossing a blood-brain barrier, a preparation method therefor and a use thereof. The oncolytic virus preparation is an oncolytic virus modified by a polypeptide having a function of crossing a blood-brain barrier. The polypeptide having the function of crossing the blood-brain barrier is RVG29-Cys. The oncolytic virus is a genetically engineered oncolytic virus OH2 in which neurotoxic and immunosuppressive genes in a wild-type virus genome are knocked out and an immune-enhancing human granulocyte-macrophage colony stimulating factor gene is inserted. An OH2-PEG-RVG nanosystem is constructed by conjugating NHS-PEG-Mal to OH2, and then coupling a Mal group on NHS-PEG-Mal to a Cys group on RVG29-Cys, thus increasing the aqueous solubility of a drug while facilitating the therapeutic drug crossing of the blood-brain barrier to treat brain tumors, and preventing neutralizing antibodies and macrophages in vivo from neutralizing and phagocytosing the oncolytic virus, thereby prolonging the circulation time in vivo.

The invention relates to vaccination with immune-isolated cells producing immunomodulators. Provided herein are vaccine compositions containing at least one retrievable biocompatible macrocapsule containing immune-isolated allogeneic cells that secrete an immunomodulator, such as GM-CSF (granulocyte-macrophage colony stimulating factor), and an antigen component (e.g., autologous tumor cells or infectious factors). Also provided herein are kits and pharmaceutical compositions containing the vaccine compositions and said products for use in methods of therapeutic or prophylactic vaccination against tumors or infectious factors.

The present disclosure relates to methods of treating severe asthma in a subject using compounds that bind to CD131 and inhibit signalling of interleukin (IL) 5 and granulocyte-macrophage colony stimulating factor (GM-CSF).

The present invention relates to gene therapy agents for the treatment of pulmonary alveolar proteinosis (PAP), particularly autoimmune PAP (aPAP). Specifically, the present invention relates to gene therapy vectors that drive transient and / or low-level expression of granulocyte-macrophage colony-stimulating factor (GM-CSF), resulting in a therapeutic effect without the toxicity associated with the therapy. The present invention further relates to related products and animal models of aPAP.

The invention relates to the technical field of cell biology, in particular to a culture medium for inducing blood-derived cells to be transformed into (muscle) fibroblasts as well as an induction method and application of the culture medium. According to the culture medium provided by the invention, growth factors and bioactive substances with proper concentrations are compounded in a basic culture medium; mononuclear macrophage activating cytokines or substances (macrophage colony stimulating factors or phorbol ester) and macrophage to (muscle) fibroblast transformation inducing factors (transforming growth factors-beta and platelet-derived growth factors-BB) are used, and patient tissue does not need to be cut. Human blood-derived cells (peripheral blood mononuclear cells or mononuclear macrophages) can be converted into (muscle) fibroblasts capable of expressing collagen and smooth muscle protein, and the method can be used for scientific research, regenerative medicine or anti-aging treatment.

The invention discloses a pichia pastoris genetic engineering strain for expressing a recombinant human granulocyte-macrophage colony stimulating factor as well as a construction method and application of the pichia pastoris genetic engineering strain. The pichia pastoris genetic engineering strain GGM4 is classified and named as pichia pastoris (syn.Komagatapha phaffii), and the preservation number of the pichia pastoris genetic engineering strain GGM4 is CGMCC (China General Microbiological Culture Collection Center) No.39117. The engineering strain is obtained by using a pichia pastoris endogenous secretory signal peptide PRY2 and a saccharomyces cerevisiae secretory signal peptide alpha MF in a combined manner and overexpressing pichia pastoris endogenous genes PDI1, SSA4 and SNC2, so that high-efficiency expression of the recombinant human granulocyte-macrophage colony stimulating factor is realized. After the strain is subjected to high-density fermentation in a 3L fermentation tank, the titer of the recombinant human granulocyte-macrophage colony stimulating factor in a fermentation supernatant is greater than 4g / L. The strain can express a high-titer recombinant human granulocyte-macrophage colony stimulating factor, and has wide industrial application value in the field of recombinant protein drug production.

The present disclosure relates to the treatment of neurodegenerative or neurological diseases or disorders with granulocyte-macrophage colony-stimulating factor.

The present invention relates to a method of treating cancer by delivering lipid nanoparticles (LNP) encapsulating an immunostimulant mRNA and a bispecific antibody mRNA into a cancer cell or tumor. The method comprises a step of injection administration of LNP encapsulating mRNA to a tumor focus of a cancer subject. An immunologic stimulant mRNA-LNP can activate immune cells at a tumor site and around the tumor site, and the immune cells, an antibody coded by a bispecific antibody mRNA-LNP and PBMC have a synergistic effect, so that local and distant metastatic tumors are effectively targeted. The preferred immunostimulatory agent is a granulocyte-macrophage colony stimulating factor (GM-CSF), an interleukin-12 (IL-12), and a combination thereof.

The invention relates to the technical field of immunodetection, in particular to a granulocyte-macrophage colony stimulating factor determination kit and a detection method thereof. The granulocyte-macrophage colony stimulating factor determination kit comprises GM-CSF magnetic particles, a GM-CSF luminous marker, an analysis buffer solution, a calibrator 1, a calibrator 2, a quality control product 1 and a quality control product 2, the GM-CSF magnetic particles, a sample or a calibration product or a quality control product and an analysis buffer solution are sequentially added, incubation cleaning is performed, then a GM-CSF luminous marker is added, incubation cleaning is performed, then a substrate A solution and a substrate B solution are sequentially added, the luminous intensity is immediately measured, the GM-CSF concentration is calculated according to a calibration curve, the total detection time can be controlled to be about 1 hour, the detection efficiency is greatly improved, and the detection cost is reduced. The detection method is simple and convenient to operate, the result is rapid and accurate, and automatic high-throughput detection is easy to realize.

The invention discloses an adeno-associated virus AAV vector. The adeno-associated virus AAV vector comprises a cytokine gene, the cell factor is selected from any one or more than two of the following components: human interleukin 2 (IL2), human interleukin 3 (IL3), human interleukin 6 (IL6), human interleukin 15 (IL15), human thrombopoietin (THPO), human stem cell factor (SCF) and human granulocyte-macrophage colony stimulating factor (GM-CSF). The invention also discloses an AAV vector combination comprising any two or more than three AAV vectors mentioned above. The invention also discloses an application of the AAV vector and a combination of the AAV vector in construction of immune system humanized non-human animals. The invention further discloses a method for constructing the immune system humanized non-human animal.

The method for producing human macrophages comprises a culture step of culturing human hematopoietic progenitor cells in a culture medium that does not substantially contain either a macrophage colony stimulating factor or a granulocyte-macrophage colony stimulating factor in the presence of a TREM2 signal activator.

The invention relates to a construction method of a peripheral red blood cell humanized mouse, which comprises the following steps: transplanting human hematopoietic stem cells into the mouse and then applying a red blood cell inducer to the mouse, or applying a red blood cell inducer to the mouse and then infusing human red blood cells into the mouse. The red blood cell inducer comprises an antibody targeting mouse macrophage, dexamethasone or a derivative thereof, and a human macrophage colony stimulating factor. In a mouse transplanted with human hematopoietic stem cells, one or more of an antibody targeting mouse macrophages, dexamethasone and a human macrophage colony stimulating factor can be used in the red blood cell induced maturation process, and high-level human red blood cell reconstruction can be quickly realized within three weeks; the maturity and the denucleation ratio of peripheral human erythrocytes reconstructed in the mouse are completely consistent with those of normal human blood; in a mouse transplanted with human erythrocytes, the erythrocyte induction process can be single treatment of an antibody or dexamethasone, or combined use of the antibody and dexamethasone. The invention also provides application of the peripheral erythrocyte humanized mouse.